Crossmark Global Holdings’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Crossmark Global Holdings’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-27,770	Closed	-$311K	–	1704
2017 Q3	$311K	Buy	+27,770	New	+$306K	0.01%	1293
2016 Q3	$311K	Buy	+27,770	New	+$302K	0.01%	1293

Crossmark Global Holdings's SCLN Position: Q4 2017 in Review

Crossmark Global Holdings sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 27,770 shares — an estimated $311K sold.

Crossmark Global Holdings first reported a position in SCLN in Q3 2016 and held it in 2 quarters. The position peaked at $311K in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.

Crossmark Global Holdings reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
Crossmark Global Holdings sold 27,770 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $311K.
Crossmark Global Holdings first reported a position in Sciclone Pharmaceuticals Inc in Q3 2016 and held it in 2 quarters.
Crossmark Global Holdings's Sciclone Pharmaceuticals Inc position peaked at $311K in Q3 2017.
0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.

Based on Crossmark Global Holdings's 13F filing for Q4 2017, filed 5 Feb 2018.